Mechanism of action Mechanism of action. Details see text. The drug consists of the cytotoxin<unk>  and the thymidine phosphorylase inhibitor (TPI)<unk> .<unk>  is incorporated into DNA during DNA synthesis and inhibits tumor cell growth.<unk>  (TFT) is incorporated into DNA by phosphorylation by thymidylate kinase (TK) to TF-TMP; TF-TMP then covalently binds to tyrosine 146 of the active site of thymidylate synthase (TS) inhibiting the enzyme's activity. TS is vital to the synthesis of DNA because it is an enzyme involved in the synthesis of the deoxynucleotide, thymidine triphosphate (dTTP). Inhibition of TS depletes the cell of dTTP and causes accumulation of deoxyuridine monophosphate (dUMP), which increases the likelihood that uracil gets misincorporated into the DNA. Also, subsequent phosphorylations of TF-TMP cause an increased level of TF-TTP within the cell, which results in it being incorporated into DNA. Even though the exact mechanism of how TFT causes DNA damage is not completely understood, it is hypothesized that the incorporation TF-TTP in DNA leads to DNA strand break formation.<unk>  prevents the degradation of<unk>  via thymidine phosphorylase (TP) when taken orally and also has antiangiogenic properties.
Trifluridine/tipiracil
Decitabine/cedazuridine
Tegafur/gimeracil/oteracil
Trastuzumab/hyaluronidase
Bortezomib/dexamethasone
Trastuzumab emtansine
Daunorubicin/cytarabine
Decitabine